新藥展現治療胰臟癌的前景
New drug shows promise in treating pancreatic cancer
Updated at: August 1, 2026 at 12:30 AM
胰臟癌長期以來一直是最難治療的疾病之一，但一項醫學突破帶來了新的希望。
Pancreatic cancer has long been one of the most challenging diseases to treat, but a medical breakthrough is offering new hope.
一種名為 daraxonrasib 的藥物（前身為 RMC-6236）被腫瘤科醫師譽為具有突破性（game-changer）的變革。
A drug called daraxonrasib, formerly known as RMC-6236, is being hailed by oncologists as a game-changer.
數十年來，驅動約 90% 胰臟癌的 KRAS 基因突變因該蛋白質缺乏傳統藥物的結合位點，而被認為是「不可成藥」（undruggable）的。
For decades, the KRAS gene mutation, which drives about 90% of pancreatic cancers, was considered 'undruggable' because the protein lacked a binding site for traditional medicine.
Daraxonrasib 通過作為一種「分子膠」（molecular glue），連接輔助蛋白質以阻斷 KRAS 生長訊號，從而克服了這一點。
Daraxonrasib overcomes this by acting as a 'molecular glue,' linking to a helper protein to block KRAS growth signals.
在 RASolute 302 試驗中，使用該藥物的患者中位存活時間較標準化療翻了一倍，從 6.7 個月延長至 13.2 個月。
In the RASolute 302 trial, patients using the drug saw their median survival time double compared to standard chemotherapy, increasing from 6.7 to 13.2 months.
由於它是一種口服藥丸，因此比傳統的靜脈注射治療更容易管理，且副作用也較少。
Because it is an oral pill, it is also easier to manage and results in fewer side effects than traditional intravenous treatments.
儘管目前正等待 FDA 的最終批准，但該藥物代表了一個重大的典範轉移。
While currently awaiting final FDA approval, the drug represents a major paradigm shift.
